Table 8.

Available sets of MHC class II-restricted neoantigens validated to elicit a CD4+ T cell response.

Author and Year	Tumor Type	Neoantigens Tested : Immunogenic Neoantigens	Available Sequencing Data	Mutations Tested	Prioritization Method	Validation Method
Ott et al., 2017 (6)	Melanoma	165:80	WES, RNAseq	SNVs and small indels	NetMHCpan2.4 and oncogene mutations	ELISPOT
Sahin et al., 2017 (7)	Melanoma	125:60	WES, RNAseq	SNVs	RNA expression > 10 RPKM and IEDB binding predictions	ELISPOT

Datasets were only included if they included a minimum of ten neoantigens.